166 related articles for article (PubMed ID: 35343258)
1. Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial.
Cheng K; Zhou YW; Chen Y; Li ZP; Qiu M; Liu JY
Cancer Control; 2022; 29():10732748221080332. PubMed ID: 35343258
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
Chen Y; Zhou YW; Cheng K; Li ZP; Luo DY; Qiu M; Li Q; Wang X; Shen YL; Cao D; Yang Y; Bi F; Liu JY; Gou HF
Oncologist; 2021 Aug; 26(8):e1320-e1326. PubMed ID: 33830591
[TBL] [Abstract][Full Text] [Related]
3. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
4. S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
Chen Y; Wu J; Cheng K; Li ZP; Luo DY; Qiu M; Gou HF; Yi C; Li Q; Wang X; Yang Y; Cao D; Shen YL; Bi F; Liu JY
Oncologist; 2019 May; 24(5):591-e165. PubMed ID: 30651398
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.
Ghiringhelli F; Vincent J; Bengrine L; Borg C; Jouve JL; Loffroy R; Guiu B; Blanc J; Bertaut A
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2357-2363. PubMed ID: 31273511
[TBL] [Abstract][Full Text] [Related]
6. A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer.
Huang M; Yang Y; Zhu X; Chen Z; Zhang W; Wang C; Zhang X; Qiu L; Zhang Z; Zhao X; Li W; Wang Y; Guo W
Asia Pac J Clin Oncol; 2021 Dec; 17(6):513-521. PubMed ID: 33567129
[TBL] [Abstract][Full Text] [Related]
7. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
Shi Y; Li J; Xu J; Sun Y; Wang L; Cheng Y; Liu W; Sun G; Chen Y; Bai L; Zhang Y; He X; Luo Y; Wang Z; Liu Y; Yao Q; Li Y; Qin S; Hu X; Bi F; Zheng R; Ouyang X
Cancer Commun (Lond); 2019 May; 39(1):28. PubMed ID: 31126331
[TBL] [Abstract][Full Text] [Related]
8. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Feliu J; Castañón C; Salud A; Mel JR; Escudero P; Pelegrín A; López-Gómez L; Ruiz M; González E; Juárez F; Lizón J; Castro J; González-Barón M;
Br J Cancer; 2005 Nov; 93(11):1230-5. PubMed ID: 16265344
[TBL] [Abstract][Full Text] [Related]
10. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer.
Scheithauer W; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Gedlicka C; Schüll B; Brugger S; Schneeweiss B; Lang F; Lenauer A; Depisch D
J Clin Oncol; 2002 Jan; 20(1):165-72. PubMed ID: 11773166
[TBL] [Abstract][Full Text] [Related]
11. Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen.
Schüll B; Kornek GV; Schmid K; Raderer M; Ulrich-Pur H; Fiebiger W; Schneeweiss B; Lenauer A; Depisch D; Scheithauer W
Onkologie; 2002 Aug; 25(4):358-62. PubMed ID: 12232488
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
13. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Tanioka H; Honda M; Tanaka C; Morita Y; Ishibashi K; Kato T; Matsuda C; Kataoka M; Satake H; Munemoto Y; Kobayashi K; Takahashi M; Nakata K; Sakamoto J; Oba K; Mishima H
Int J Clin Oncol; 2019 Jul; 24(7):836-841. PubMed ID: 30778794
[TBL] [Abstract][Full Text] [Related]
14. [Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
Schüll B; Scheithauer W
Acta Med Austriaca; 2002; 29(4):124-31. PubMed ID: 12424937
[TBL] [Abstract][Full Text] [Related]
15. First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study.
Gallois C; Hafliger E; Auclin E; Perret A; Coutzac C; Turpin A; Pellat A; Randrian V; Basile D; Faroux R; Pernot S; Locher C; Hautefeuille V; Dubreuil O; Palmieri LJ; Dior M; Artru P; Taieb J
Dig Liver Dis; 2022 May; 54(5):684-691. PubMed ID: 34470724
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan and raltitrexed: an active combination in advanced colorectal cancer.
Carnaghi C; Rimassa L; Garassino I; Zucali PA; Masci G; Fallini M; Morenghi E; Santoro A
Ann Oncol; 2002 Sep; 13(9):1424-9. PubMed ID: 12196368
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study).
Suzuki N; Hazama S; Nagasaka T; Tanioka H; Iwamoto Y; Negoro Y; Yamauchi M; Kobayashi M; Okuda H; Fujishima N; Nishimura T; Yamanaka N; Toyota K; Mori Y; Nakagami Y; Shimokawa M; Nagano H; Okajima M
Int J Clin Oncol; 2019 Oct; 24(10):1223-1230. PubMed ID: 31144145
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
Osumi H; Shinozaki E; Mashima T; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Ota Y; Nakayama I; Takahari D; Chin K; Miki Y; Yamaguchi K
Cancer Sci; 2018 Aug; 109(8):2567-2575. PubMed ID: 29908105
[TBL] [Abstract][Full Text] [Related]
19. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
Dai X; Tao L; Wang J; Wu W; Bian W; Dai X; Chen S
Cancer Med; 2023 Aug; 12(15):16108-16118. PubMed ID: 37325938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
